TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Undercarboxylated Osteocalcin (ucOC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feno concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Verbal fluency performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time needed for dressing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overnight nadir BG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hyperglycemia (≥250 mg/dL)
Endpoint domain: Adverse events/effects
Primary endpoint: Absorption of amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total body weight, lean body mass, and body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participation improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abstinence rates from cannabis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SPID scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief (TOTPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global evaluation of treatment effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cervical spine motion during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CILP (Cumulative Incidence of Local Progression)
Endpoint domain: Mortality/survival
Primary endpoint: Ankle brachial index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: DeltaPmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBF (Cerebral Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trait anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of sleep score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Recurrence of keloids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: complete mycological cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of minimal sedation colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: BIS values corresponding to 95% probability of ablating response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AE values corresponding to 95% probability of ablating response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Second-meal glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Second-meal insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FFA rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of colorectal liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PSAF)
Endpoint domain: Mortality/survival
Primary endpoint: Bath AS Functional Index (BASFI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMFM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flSMN mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diarrhoea prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of exclusive or predominant breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBPS score ≥5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemagglutination inhibition antibody titers of 1:40 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean titer responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BMD testing achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of allergic rash, itching, sedation and respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Sedation score
Endpoint domain: Adverse events/effects
Primary endpoint: Fraction of time with pH < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean score of GSS at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscular strength in hip abductors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximum hip adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pelvic drop during weight acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in speed of correctly resolved items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of recurrent MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased risk for venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: symptom scores of dyspepsia components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to all-cause discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: mean reduction in storage subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in voiding subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of clinical pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in hand tremor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less clinical decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attendance at the initial follow‐up appointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bicarbonate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactate concentration increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of ET-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary oxygenation function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative dehydration of lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of terminal SC5b‐9 complement complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Buccal volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interproximal bone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective improvement in motion analysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrosternal microcirculation deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of impersonal events
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Details of recent impersonal events
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity grade of acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional tissue oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: creatine phosphokinase value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of being fatally injured
Endpoint domain: Mortality/survival
Primary endpoint: Relationship intimacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sensation of dryness and foreign body sensation in the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tears secretion test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lacrimal membrane breaking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: axillary hyperhidrosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma total antioxidant status (TAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood reduced glutathione (GSH) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4(+) cell concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duration of progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Sick leave rates 5 years after diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of patients free of full-symptom panic attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PDSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction-incision time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge time
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Vomiting incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of subjective increase in heart rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of biochemical leakage (BL) or postoperative pancreatic fistula (POPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in isohypercapnic ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilatory CO2 sensitivity (C50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CIPNM severity sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat mtDNA change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients who stayed >=4 nights in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decrease in VMCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine levels after caffeine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Awareness of hypoglycemia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in shade guide units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early postoperative DVT
Endpoint domain: Adverse events/effects
Primary endpoint: DVT at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: bleeding complications requiring reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excellent rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum C-peptide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: No pain or discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean N1/P2 slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-adherence to HAART
Endpoint domain: Adverse events/effects
Primary endpoint: Feeding tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Enteral caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of encrustation on the Vesair intravesical balloon
Endpoint domain: Adverse events/effects
Primary endpoint: Mean reduction in GHQ‐12 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in dysfunctional thoughts about caregiving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aerobic power (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 at lactate threshold (LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total gray matter volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: abnormal tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ischemic lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in depression (Profile of Mood States)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in immediate verbal memory recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urine flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in osteoarthritis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of endoscopically proven ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Overall parameters of the VSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Power Spectral Analysis of Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baroreceptor sensitivity (indexes b2 and b4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean outdoor time per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diabetes risk associated with antidepressant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary acetonitrile levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c level < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma glucose (FPG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of treatment for chronic back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet TF-dependent PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TF protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: recurrence of warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: symptoms of anxiety improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events due to acupuncture
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of posttreatment clinical benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive relapse rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of MIBI-SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of exercise stress testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of stress echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention rates (RET)
Endpoint domain: Mortality/survival
Primary endpoint: Marginal adaptation (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in HbA1c concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving HbA1c target of ≤53 mmol/mol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving clinical targets (HbA1c, blood pressure, LDL cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of statins on apolipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of relapse based on T/Mu and T/Me ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Preventing stroke/SEE
Endpoint domain: Mortality/survival
Primary endpoint: modified QuickDASH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-HAQ improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of oropharyngeal candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of vaginal candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive performance on RVIP task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation (Ox%) in prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of more than 48-h lapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulinemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic arterial pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean treadmill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck and forearm T(sk) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of T(re) rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histamine wheal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalizations for worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tardive and withdrawal dyskinesias
Endpoint domain: Adverse events/effects
Primary endpoint: excessive sedation
Endpoint domain: Adverse events/effects
Primary endpoint: etiologic diagnostic rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digoxin AUC and Cmax increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lesion recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total duration of ventilation support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAP incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: duration of RICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates to a postal health questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes